Disease-specific survival curves for VEGF-C and VEGFR-3 in the total material and in the group with wide and non-wide resection margins.

<p>(A) VEGF-C, total material; (B) VEGF-C, wide resection margins; (C) VEGF-C, non-wide resection margins; (D) VEGFR-3, total material; (E) VEGFR-3, wide resection margins; (F) VEGFR-3, non-wide resection margins. Abbreviations: VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.</p

Prognostic relevance of clinicopathological variables for disease-specific survival in 249 non-gastrointestinal stromal tumor soft-tissue sarcomas (univariate analyses, log rank test).

<p>Abbreviations: NR, not reached; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified.</p

Tumor expression of VEGFs and VEGFRs and their prognostic relevance for disease-specific survival in patients with non-gastrointestinal soft-tissue sarcomas in the total material (univariate analyses; log-rank test, N = 249) and in subgroups with wide and non-wide resection margins (univariate analyses; log-rank test, N = 108 and 141 respectively).

<p>Abbreviations: NR, not reached.</p

Results of the Cox regression analysis of the total material.

<p>*Overall significance as a prognostic factor.</p

IHC analysis of TMA of non-GIST STSs representing different scores for tumor cell VEGF-C and VEGFR-3.

<p>(A) Tumor cell VEGF-C high score in leiomyosarcoma; (B) Tumor cell VEGF-C low score in leiomyosarcoma; (C) Tumor cell VEGFR-3 high score in undifferentiated pleomorphic sarcoma; (D) Tumor cell VEGFR-3 low score in liposarcoma. Abbreviations: IHC, immunohistochemistry; non-GIST STS, non-gastrointestinal stromal tumor soft-tissue sarcoma TMA, tissue microarray; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.</p

Results of the quality assessment of the included studies by marker.

<p>Abbreviations: LNM, Lymphatic node metastasis; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD, lymphatic vascular density.</p><p>Maximal score for any given category is 1.</p

Tumor cell and stromal markers as prognostic factors for disease-specific survival in 335 NSCLC patients (univariate analyses; log-rank test).

<p>*Tumor data.</p

Prognostic clinicopathological variables as predictors for disease-specific survival in 249 non-GIST STSs (univariate analyses, log-rank test).

<p>Abbreviations: NR, not reached; MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified; non-GIST STS, non-gastro intestinal stromal tumor soft-tissue sarcoma.</p

Summarizing the aggregated analyses and their corresponding heterogeneity tests.

<p>Abbreviations: HR, hazard ratio; RR, relative risk; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD, lymphatic vascular density; NA, not applicable; Q, test for heterogeneity; P, the p-value calculated for Q; TAU², an estimate of the total amount of heterogeneity; I², the proportion of total variation in study estimates attributed to heterogeneity; H², the total variability or within study variance.</p><p>Values for unadjusted, leave1out (test conducted without the one study introducing the most heterogeneity) and adjusted (test conducted with the inclusion of studies assumed missing in case of funnel asymmetry).</p

IHC analysis of TMA of non-GIST STS representing different scores of expression of dedifferentiation related markers in tumor cells.

<p>A, Leiomyosarcoma, histological grade I, E-cadherin, negative staining, score 0; B, Dedifferentiated liposarcoma, histological grade II, TGF-β1, weak staining, score 1; C, Pleomorphic liposarcoma, histological grade III, Fascin, moderate staining; score 2; D, Alveolar rhabdomyosarcoma, histological grade III, Vimentin, strong staining, score 3. All calibration bars correspond to 100 µm. Abbreviations; IHC, immunohistochemistry; TMA, tissue microarray; non-GIST STS, non gastro-intestinal stromal tumor soft-tissue sarcoma; TGF-β1, transforming growth factor beta 1.</p